Heron Therapeutics (NASDAQ:HRTX - Get Free Report) is expected to be releasing its earnings data before the market opens on Tuesday, March 11th. Analysts expect Heron Therapeutics to post earnings of ($0.03) per share and revenue of $37.37 million for the quarter. Heron Therapeutics has set its FY 2025 guidance at EPS.Persons that are interested in participating in the company's earnings conference call can do so using this link.
Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.05. The business had revenue of $40.78 million for the quarter, compared to the consensus estimate of $37.37 million. On average, analysts expect Heron Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Heron Therapeutics Trading Up 1.3 %
Shares of NASDAQ:HRTX traded up $0.03 on Friday, reaching $2.39. The company had a trading volume of 1,532,645 shares, compared to its average volume of 1,875,962. The firm has a market capitalization of $363.51 million, a PE ratio of -13.28 and a beta of 1.60. Heron Therapeutics has a 52-week low of $1.04 and a 52-week high of $3.93. The firm's 50 day simple moving average is $1.75 and its 200-day simple moving average is $1.73.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on HRTX shares. Needham & Company LLC reissued a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a research report on Friday, February 28th. StockNews.com raised shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a report on Friday, February 28th.
Read Our Latest Research Report on HRTX
About Heron Therapeutics
(
Get Free Report)
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Stories
Before you consider Heron Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.
While Heron Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
